S&P 500   4,550.58 (-0.09%)
DOW   35,430.42 (+0.04%)
QQQ   389.81 (-0.10%)
AAPL   189.37 (-0.54%)
MSFT   378.85 (-1.01%)
META   332.20 (-2.00%)
GOOGL   134.99 (-1.61%)
AMZN   146.32 (-0.48%)
TSLA   244.14 (-1.05%)
NVDA   481.40 (+0.67%)
NIO   7.18 (-0.42%)
BABA   74.67 (-2.70%)
AMD   123.85 (+1.51%)
T   16.30 (+0.74%)
F   10.59 (+2.12%)
MU   76.69 (+0.75%)
CGC   0.56 (+3.65%)
GE   118.86 (+0.01%)
DIS   92.50 (+0.00%)
AMC   7.17 (+7.01%)
PFE   30.08 (+1.31%)
PYPL   57.97 (-0.86%)
XOM   102.34 (-1.50%)
S&P 500   4,550.58 (-0.09%)
DOW   35,430.42 (+0.04%)
QQQ   389.81 (-0.10%)
AAPL   189.37 (-0.54%)
MSFT   378.85 (-1.01%)
META   332.20 (-2.00%)
GOOGL   134.99 (-1.61%)
AMZN   146.32 (-0.48%)
TSLA   244.14 (-1.05%)
NVDA   481.40 (+0.67%)
NIO   7.18 (-0.42%)
BABA   74.67 (-2.70%)
AMD   123.85 (+1.51%)
T   16.30 (+0.74%)
F   10.59 (+2.12%)
MU   76.69 (+0.75%)
CGC   0.56 (+3.65%)
GE   118.86 (+0.01%)
DIS   92.50 (+0.00%)
AMC   7.17 (+7.01%)
PFE   30.08 (+1.31%)
PYPL   57.97 (-0.86%)
XOM   102.34 (-1.50%)
S&P 500   4,550.58 (-0.09%)
DOW   35,430.42 (+0.04%)
QQQ   389.81 (-0.10%)
AAPL   189.37 (-0.54%)
MSFT   378.85 (-1.01%)
META   332.20 (-2.00%)
GOOGL   134.99 (-1.61%)
AMZN   146.32 (-0.48%)
TSLA   244.14 (-1.05%)
NVDA   481.40 (+0.67%)
NIO   7.18 (-0.42%)
BABA   74.67 (-2.70%)
AMD   123.85 (+1.51%)
T   16.30 (+0.74%)
F   10.59 (+2.12%)
MU   76.69 (+0.75%)
CGC   0.56 (+3.65%)
GE   118.86 (+0.01%)
DIS   92.50 (+0.00%)
AMC   7.17 (+7.01%)
PFE   30.08 (+1.31%)
PYPL   57.97 (-0.86%)
XOM   102.34 (-1.50%)
S&P 500   4,550.58 (-0.09%)
DOW   35,430.42 (+0.04%)
QQQ   389.81 (-0.10%)
AAPL   189.37 (-0.54%)
MSFT   378.85 (-1.01%)
META   332.20 (-2.00%)
GOOGL   134.99 (-1.61%)
AMZN   146.32 (-0.48%)
TSLA   244.14 (-1.05%)
NVDA   481.40 (+0.67%)
NIO   7.18 (-0.42%)
BABA   74.67 (-2.70%)
AMD   123.85 (+1.51%)
T   16.30 (+0.74%)
F   10.59 (+2.12%)
MU   76.69 (+0.75%)
CGC   0.56 (+3.65%)
GE   118.86 (+0.01%)
DIS   92.50 (+0.00%)
AMC   7.17 (+7.01%)
PFE   30.08 (+1.31%)
PYPL   57.97 (-0.86%)
XOM   102.34 (-1.50%)

HAVN Life Sciences Stock Price, News & Analysis (OTCMKTS:HAVLF)

$0.01
-0.02 (-57.14%)
(As of 04:20 PM ET)
Compare
Today's Range
$0.01
$0.02
50-Day Range
$0.01
$0.03
52-Week Range
$0.00
$0.10
Volume
2,182 shs
Average Volume
14,897 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

HAVLF stock logo

About HAVN Life Sciences Stock (OTCMKTS:HAVLF)

HAVN Life Sciences Inc., a biotechnology company, engages in the research and development of psychopharmacological products from plants and fungi. The Company also focuses on developing methodologies for the standardize and quality-controlled extraction of psychoactive compounds from plants and fungi, including Psilocybe spp. mushrooms; and the genera directive compounds, such as psilocybin, psilocin, and baeocystin, as well as the development of natural health care products from non-regulated compounds. The company was incorporated in 2020 and is headquartered in Richmond, Canada.

HAVLF Stock Price History

HAVLF Stock News Headlines

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
HAVN.CN - HAVN Life Sciences Inc.
HAVN Life Sciences Inc (HAVN)
HAVN Life Provides Corporate Update
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
HAVN Life Sciences Inc. (HAVLF)
IIROC Trading Halt - HAVN
IIROC Trade Resumption - HAVN
HAVN Life enters supply agreement with MPB Group
HAVN Life Launches the Brain Evolve Series
See More Headlines
Receive HAVLF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for HAVN Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
11/29/2023
Next Earnings (Estimated)
1/15/2024

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:HAVLF
CIK
N/A
Phone
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Tim Moore (Age 64)
    Interim CFO, CEO & Chairman
    Comp: $126.05k
  • Ms. Jenna Pozar
    Chief Operations Officer
  • Mr. Paul More
    Controller














HAVLF Stock Analysis - Frequently Asked Questions

How have HAVLF shares performed in 2023?

HAVN Life Sciences' stock was trading at $0.0595 at the beginning of 2023. Since then, HAVLF shares have decreased by 79.8% and is now trading at $0.0120.
View the best growth stocks for 2023 here
.

Are investors shorting HAVN Life Sciences?

HAVN Life Sciences saw a decrease in short interest in November. As of November 15th, there was short interest totaling 100 shares, a decrease of 99.6% from the October 31st total of 27,600 shares. Based on an average trading volume of 600 shares, the days-to-cover ratio is presently 0.2 days.
View HAVN Life Sciences' Short Interest
.

When is HAVN Life Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, January 15th 2024.
View our HAVLF earnings forecast
.

When did HAVN Life Sciences' stock split?

HAVN Life Sciences shares reverse split on the morning of Wednesday, August 3rd 2022. The 1-30 reverse split was announced on Wednesday, August 3rd 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, August 3rd 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

How do I buy shares of HAVN Life Sciences?

Shares of HAVLF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (OTCMKTS:HAVLF) was last updated on 11/29/2023 by MarketBeat.com Staff

My Account -